Chabiotech Co.,Ltd. (KOSDAQ:085660)

Market Cap	1.61T +167.0%
Revenue (ttm)	1.27T +21.4%
Net Income	-109.88B
EPS	-1,637.00
Shares Out	92.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	307,941
Average Volume	297,220
Open	17,450
Previous Close	17,400
Day's Range	17,050 - 17,660
52-Week Range	9,690 - 23,950
Beta	0.67
RSI	41.74
Earnings Date	May 14, 2026

About Chabiotech

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 278
• Stock Exchange: KOSDAQ
• Ticker Symbol: 085660

Financial Performance

In 2025, Chabiotech's revenue was 1.27 trillion, an increase of 21.36% compared to the previous year's 1.05 trillion. Losses were -109.88 billion, 2206.6% more than in 2024.